What is the appropriate acyclovir dosing for a multiple myeloma patient with active herpes simplex virus (HSV) or varicella‑zoster virus (VZV) infection versus when the patient is in remission and requires prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Acyclovir Dosing for Multiple Myeloma Patients: Active HSV/VZV Infection vs. Prophylaxis

For active HSV or VZV infection in multiple myeloma patients, use intravenous acyclovir 5-10 mg/kg every 8 hours; for prophylaxis during remission or while receiving proteasome inhibitors, anti-CD38 antibodies, or BCMA-targeted therapies, use oral acyclovir 400 mg once daily.

Active Disease Treatment

When a multiple myeloma patient develops active HSV or VZV infection, treatment intensity depends on disease severity:

For Active HSV Infection:

  • Mild to moderate mucocutaneous disease: Oral acyclovir 400 mg five times daily or valacyclovir 1, 2
  • Severe or disseminated HSV: Intravenous acyclovir 5 mg/kg every 8 hours for 7 days 1
  • HSV encephalitis: Intravenous acyclovir 10 mg/kg every 8 hours for 10 days 1

For Active VZV Infection (Herpes Zoster):

  • Localized zoster: Oral acyclovir 800 mg five times daily 3, 4
  • Disseminated or severe VZV: Intravenous acyclovir 10 mg/kg every 8 hours (500 mg/m² every 8 hours) for 7 days 1

The FDA label clearly demonstrates that immunocompromised patients with localized HSV or VZV infections responded to these dosing regimens in controlled trials 1. For acyclovir-resistant cases (which occur in immunocompromised patients), foscarnet 40 mg/kg three times daily or 60 mg/kg twice daily becomes the alternative 5, 3.

Prophylaxis During Remission

The most recent and authoritative guideline from EHA-EMN (2025) explicitly recommends acyclovir or valacyclovir for herpes zoster prophylaxis in multiple myeloma patients receiving proteasome inhibitors, anti-CD38 antibodies, and BCMA-targeted therapies 6.

Prophylactic Dosing:

  • Standard prophylaxis: Acyclovir 400 mg once daily 7, 8, 9
  • Alternative: Valacyclovir or famciclovir at equivalent doses 6, 10

The evidence strongly supports this low-dose regimen:

  • In a retrospective study of 100 MM patients receiving bortezomib-based therapy, zero patients developed herpes zoster when receiving acyclovir 400 mg twice daily 7
  • Korean and European studies confirmed that acyclovir 400 mg once daily was sufficient—no herpes zoster occurred in patients receiving this dose throughout bortezomib treatment 8, 9
  • After autologous stem cell transplantation, low-dose acyclovir 400 mg daily for 12 months reduced HZ incidence from 20% to 2.8% 11

Duration of Prophylaxis:

  • During active treatment: Continue throughout therapy with high-risk agents (proteasome inhibitors, anti-CD38 antibodies, BCMA-targeted therapies) and for at least 4 weeks after completion 6, 7
  • Post-autologous transplant: Continue for 6-12 months 10, 11
  • High-risk patients: Consider extending prophylaxis if receiving ongoing immunosuppression or have history of frequent reactivations 10

Critical Considerations

Renal Dose Adjustments:

Both treatment and prophylactic doses require adjustment in renal impairment, which is common in multiple myeloma. The FDA label provides specific guidance, though not fully detailed in the excerpts provided 1, 2. Standard practice reduces frequency based on creatinine clearance.

Risk Stratification:

The NCCN guidelines (2024) identify MM patients as intermediate-to-high risk for HSV/VZV reactivation, particularly those receiving:

  • Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)
  • Anti-CD38 antibodies (daratumumab, isatuximab)
  • BCMA-targeted therapies
  • High-dose corticosteroids
  • T-cell depleting agents 10

Common Pitfall:

Do not use the same low prophylactic dose (400 mg once daily) for active infection—this is inadequate and risks developing acyclovir resistance 1, 2. Active disease requires 5-10 times higher daily doses.

Resistance Monitoring:

If a patient shows poor clinical response to standard acyclovir treatment doses after 5-7 days, suspect resistance and obtain viral cultures with susceptibility testing. Switch to foscarnet rather than increasing acyclovir further 5, 3.

The evidence base is remarkably consistent: prophylactic acyclovir 400 mg once daily is highly effective and well-tolerated in multiple myeloma patients, while active infections require substantially higher doses administered more frequently 6, 7, 8, 9.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.